






# Paper E analysis update

02/02/2017







Original  
Random





# coding



# noncoding









**A**


non-neutral passenger signature







neutral passenger signature



**B**

all non-coding (N=513578)












Pancancer Deletions











Pancancer Duplications







genes by earliest mean LOF event







Survival curves for Lymph-CLL and Kidney-RCC patients, stratified by Somatic Impact Burden relative to corresponding randomized sets, with 95% confidence intervals. Survival for patients in the top quartile by cancer subtype of Somatic Impact Burden is in pink, blue for the bottom quartile.